LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "pseudoprogression" as a keyword



Photo by cesarfrv93 from unsplash

Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies

Sign Up to like & get
recommendations! Published in 2018 at "JAMA Oncology"

DOI: 10.1001/jamaoncol.2017.5332

Abstract: Importance Longitudinal circulating tumor DNA (ctDNA) has been shown to predict response and survival in patients with metastatic melanoma treated with anti–programmed cell death 1 (PD-1) antibodies. Pseudoprogression, defined as radiologic finding of disease progression… read more here.

Keywords: ctdna; response; ctdna profile; disease ... See more keywords
Photo by nci from unsplash

Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types

Sign Up to like & get
recommendations! Published in 2020 at "Cancer Medicine"

DOI: 10.1002/cam4.2797

Abstract: PD(L)1 antibodies (anti‐PD(L)‐1) have been a major breakthrough in several types of cancer. Novel patterns of response and progression have been described with anti‐PD(L)‐1. We aimed at characterizing pseudoprogression (PSPD) among patients with various solid… read more here.

Keywords: tumor types; patients treated; evidence pseudoprogression; pseudoprogression ... See more keywords
Photo by 90angle from unsplash

Pushing the limits of immune-related response: a case of “extreme pseudoprogression”

Sign Up to like & get
recommendations! Published in 2018 at "Cancer Immunology, Immunotherapy"

DOI: 10.1007/s00262-018-2167-3

Abstract: The advent of immune checkpoint targeted immunotherapy has seen a spectrum of immune-related phenomena in both tumor responses and toxicities. We describe a case of pseudoprogression that pushes the limits of immune-related response criteria and… read more here.

Keywords: limits immune; immune related; case; related response ... See more keywords
Photo by mojaghrout from unsplash

DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy

Sign Up to like & get
recommendations! Published in 2019 at "Journal of Neuro-Oncology"

DOI: 10.1007/s11060-019-03379-6

Abstract: Purpose It can be challenging to differentiate pseudoprogression from progression. We assessed the ability of dynamic contrast enhanced T1 MRI (DCE-MRI) perfusion to identify pseudoprogression in melanoma brain metastases. Methods Patients with melanoma brain metastases… read more here.

Keywords: pseudoprogression; dce mri; progression; mri perfusion ... See more keywords
Photo by finnnyc from unsplash

Pseudoprogression after glioma therapy: an update

Sign Up to like & get
recommendations! Published in 2017 at "Expert Review of Neurotherapeutics"

DOI: 10.1080/14737175.2017.1375405

Abstract: ABSTRACT Introduction: Initial diagnostics and follow-up of gliomas is usually based on contrast-enhanced MRI. However, the capacity of standard MRI to differentiate neoplastic tissue from posttherapeutic effects such as pseudoprogression is limited. Advanced neuroimaging methods… read more here.

Keywords: pseudoprogression; glioma therapy; pwi; pseudoprogression glioma ... See more keywords
Photo by adrienolichon from unsplash

Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression

Sign Up to like & get
recommendations! Published in 2019 at "Neuro-Oncology"

DOI: 10.1093/neuonc/noy160

Abstract: BACKGROUND Noninvasively differentiating therapy-induced pseudoprogression from recurrent disease in patients with glioblastoma is prospectively difficult due to the current lack of a biologically specific imaging metric. Ferumoxytol iron oxide nanoparticle MRI contrast characterizes innate immunity… read more here.

Keywords: ferumoxytol gadolinium; contrast; pseudoprogression; oncology ... See more keywords
Photo from wikipedia

Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma

Sign Up to like & get
recommendations! Published in 2018 at "Thoracic Cancer"

DOI: 10.1111/1759-7714.12872

Abstract: Nivolumab, an anti‐PD‐1 antibody, has been shown to be effective in many cancers, such as malignant melanoma and lung cancer; however, nivolumab therapy can result in pseudoprogression. Diffuse alveolar hemorrhage (DAH) is persistent or recurrent… read more here.

Keywords: therapy; hemorrhage; nivolumab therapy; malignant melanoma ... See more keywords
Photo by windclems from unsplash

FLAIR pseudoprogression in patients with anaplastic oligodendrogliomas treated with PCV chemotherapy alone.

Sign Up to like & get
recommendations! Published in 2023 at "European journal of neurology"

DOI: 10.1111/ene.15873

Abstract: BACKGROUND Pseudoprogression in gliomas has been extensively described after radiotherapy with or without chemotherapy, but not after chemotherapy alone. Herein, we describe the occurrence of pseudoprogression in patients with anaplastic oligodendrogliomas treated with post-operative procarbazine,… read more here.

Keywords: pseudoprogression; chemotherapy alone; anaplastic oligodendrogliomas; oligodendrogliomas treated ... See more keywords
Photo by nci from unsplash

267 Pseudoprogression patterns: Analysis from 2 independent phase-2 studies with immunotherapy for recurrent cervical cancer

Sign Up to like & get
recommendations! Published in 2020 at "Journal for ImmunoTherapy of Cancer"

DOI: 10.1136/jitc-2020-sitc2020.0267

Abstract: Background The phenomenon of pseudoprogression (PsP) may appear with cancer immunotherapy. The underlying etiology is not fully elucidated, tumor flare is the suspected mechanism of early pseudoprogression that may resolve gradually while continuing treatment. Further,… read more here.

Keywords: psp; cervical cancer; cancer; pseudoprogression ... See more keywords
Photo by jonasvincentbe from unsplash

Diagnosis of Pseudoprogression Following Lomustine–Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET

Sign Up to like & get
recommendations! Published in 2021 at "Clinical Cancer Research"

DOI: 10.1158/1078-0432.ccr-21-0471

Abstract: Purpose: The CeTeG/NOA-09 phase III trial demonstrated a significant survival benefit of lomustine–temozolomide chemoradiation in patients with newly diagnosed glioblastoma with methylated O6-methylguanine-DNA methyltransferase (MGMT) promoter. Following lomustine–temozolomide chemoradiation, late and prolonged pseudoprogression may occur.… read more here.

Keywords: fet pet; lomustine temozolomide; pseudoprogression; temozolomide chemoradiation ... See more keywords
Photo by schluditsch from unsplash

Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report

Sign Up to like & get
recommendations! Published in 2017 at "BMC Cancer"

DOI: 10.1186/s12885-017-3785-4

Abstract: BackgroundPseudoprogression refers to a specific pattern of response sometimes observed in malignant melanoma patients receiving treatment with immune-checkpoint inhibitors. Although cases with pseudoprogression documented once have been reported previously, there have been no case reports… read more here.

Keywords: treatment; case; treatment nivolumab; malignant melanoma ... See more keywords